These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 24812687)

  • 1. Coexistence of cardiomyopathy and pericardial effusion: A challenging diagnosis. Reply.
    Omar HR
    Herz; 2014 Mar; 39(2):225. PubMed ID: 24812687
    [No Abstract]   [Full Text] [Related]  

  • 2. Coexistence of cardiomyopathy and pericardial effusion: A challenging diagnosis.
    Yalcinkaya E
    Herz; 2014 Mar; 39(2):224. PubMed ID: 24154881
    [No Abstract]   [Full Text] [Related]  

  • 3. Glycoprotein IIb/IIIa antagonists in Takotsubo cardiomyopathy.
    Omar HR
    Herz; 2013 Nov; 38(7):740-2. PubMed ID: 23632423
    [No Abstract]   [Full Text] [Related]  

  • 4. Transvenous pacing causing tamponade in patients receiving glycoprotein IIb/IIIa inhibitors for percutaneous coronary intervention.
    Jeilan M; Richardson G; Gershlick A
    J Invasive Cardiol; 2007 Feb; 19(2):E40-2. PubMed ID: 17268050
    [No Abstract]   [Full Text] [Related]  

  • 5. Duration of action of GpIIb-IIIa antagonists.
    Johnson K
    Crit Care Nurse; 2000 Oct; 20(5):16. PubMed ID: 11878484
    [No Abstract]   [Full Text] [Related]  

  • 6. Platelet inhibition after glycoprotein IIb/IIIa inhibitor therapy.
    Galli M
    Circulation; 2001 Dec; 104(25):E163. PubMed ID: 11748127
    [No Abstract]   [Full Text] [Related]  

  • 7. Assessing platelet function during treatment with glycoprotein IIb/IIIa antagonists.
    Steinhubl SR
    Coron Artery Dis; 2003 Aug; 14(5):381-6. PubMed ID: 12878903
    [No Abstract]   [Full Text] [Related]  

  • 8. [Pathophysiology, clinical and experimental possibilities of pericardial tamponade].
    Bari G; Érces D; Varga G; Szűcs S; Bogáts G
    Orv Hetil; 2018 Feb; 159(5):163-167. PubMed ID: 29376423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The use of BP IIb/IIIa inhibitors].
    Polimeno S; De Rosa V
    Ital Heart J Suppl; 2000 Jul; 1(7):958-61. PubMed ID: 10935749
    [No Abstract]   [Full Text] [Related]  

  • 10. [Inhibitors of platelet glycoprotein IIb-IIIa in cardiology].
    Obradović S; Gligić B; Djordjević D; Jovicić A; Romanović R; Ratković N; Dincić D; Orozović V; Nikolić G
    Vojnosanit Pregl; 2001; 58(1):65-72. PubMed ID: 11419288
    [No Abstract]   [Full Text] [Related]  

  • 11. Platelet glycoprotein IIb/IIIa receptor blockade in unstable coronary disease.
    Chesebro JH; Badimon JJ
    N Engl J Med; 1998 May; 338(21):1539-41. PubMed ID: 9593795
    [No Abstract]   [Full Text] [Related]  

  • 12. Glycoprotein IIb/IIIa receptor antagonists in acute coronary syndromes.
    Zidar JP
    J Invasive Cardiol; 1999 Jun; 11 Suppl A():13A-19A. PubMed ID: 10745606
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of acute central retinal artery occlusionwith the platelet glycoprotein IIb/IIIa receptor inhibitor tirofiban.
    Hölschermann H; Krombach C; Jung A; Jacobi F; Tillmanns H; Weinand F
    Thromb Haemost; 2005 Sep; 94(3):684-6. PubMed ID: 16268493
    [No Abstract]   [Full Text] [Related]  

  • 14. [GPIIb/IIIa inhibitor].
    Ikeda Y
    Tanpakushitsu Kakusan Koso; 2000 Apr; 45(6 Suppl):1174-81. PubMed ID: 10771692
    [No Abstract]   [Full Text] [Related]  

  • 15. GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood.
    Furman MI; Krueger LA; Frelinger AL; Barnard MR; Mascelli MA; Nakada MT; Michelson AD
    Thromb Haemost; 2000 Sep; 84(3):492-8. PubMed ID: 11019977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization].
    Albuquerque A
    Rev Port Cardiol; 2001 Sep; 20(9):927-8. PubMed ID: 11763604
    [No Abstract]   [Full Text] [Related]  

  • 17. Platelet glycoprotein IIb/IIIa antagonists in percutaneous coronary interventions.
    Gambhir DS; Mukhopadhyay S
    Indian Heart J; 2000; 52(5):524-32. PubMed ID: 11256774
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment with a GPIIb/IIIa antagonist inhibits thrombin generation in platelet rich plasma from patients.
    Keularts IM; Béguin S; de Zwaan C; Hemker HC
    Thromb Haemost; 1998 Sep; 80(3):370-1. PubMed ID: 9759611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban].
    Galli M; Vassanelli C
    Ital Heart J Suppl; 2001 Oct; 2(10):1127-9. PubMed ID: 11723619
    [No Abstract]   [Full Text] [Related]  

  • 20. [Comparison of 2 platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization].
    Rossi ML; Merlini PA
    Ital Heart J Suppl; 2001 Oct; 2(10):1130-2. PubMed ID: 11723620
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.